Sonja I Buschow
Overview
Explore the profile of Sonja I Buschow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kessler A, Pieterman R, Doff W, Bezstarosti K, Bouzid R, Klarenaar K, et al.
NPJ Vaccines
. 2025 Jan;
10(1):12.
PMID: 39827205
Synthetic long peptides (SLPs) are a promising vaccine modality that exploit dendritic cells (DC) to treat chronic infections or cancer. Currently, the design of SLPs relies on in silico prediction...
2.
Marzella D, Crocioni G, Radusinovic T, Lepikhov D, Severin H, Bodor D, et al.
Commun Biol
. 2024 Dec;
7(1):1661.
PMID: 39702482
The interaction between peptides and major histocompatibility complex (MHC) molecules is pivotal in autoimmunity, pathogen recognition and tumor immunity. Recent advances in cancer immunotherapies demand for more accurate computational prediction...
3.
Kortleve D, Hammerl D, van Brakel M, Wijers R, Roelofs D, Kroese K, et al.
Cancer Discov
. 2024 Aug;
14(12):2450-2470.
PMID: 39172012
Triple-negative breast cancer (TNBC) has an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T cells. ROPN1 showed high and homogenous expression...
4.
Rakke Y, Buschow S, IJzermans J, Sprengers D
Front Immunol
. 2024 Mar;
15:1357333.
PMID: 38440738
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the first and second most common primary liver cancer (PLC). For decades, systemic therapies consisting of tyrosine kinase inhibitors (TKIs) or chemotherapy have...
5.
Jansen D, de Beijer M, Luijten R, Kwappenberg K, Wiekmeijer A, Kessler A, et al.
Front Immunol
. 2023 Oct;
14:1163118.
PMID: 37781393
Introduction: Therapeutic vaccination based on synthetic long peptides (SLP) containing both CD4+ and CD8+ T cell epitopes is a promising treatment strategy for chronic hepatitis B infection (cHBV). Methods: We...
6.
Noordam L, de Beijer M, Mancham S, Vogler I, Boor P, de Ruiter V, et al.
Oncoimmunology
. 2022 Oct;
11(1):2131096.
PMID: 36211805
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide due to high recurrence rates after curative treatment and being frequently diagnosed at an advanced stage. Immune-checkpoint inhibition...
7.
de Beijer M, Bezstarosti K, Luijten R, Doff W, Boor P, Pieterman R, et al.
JHEP Rep
. 2022 Oct;
4(11):100576.
PMID: 36185575
Background & Aims: Antigen-specific immunotherapy is a promising strategy to treat HBV infection and hepatocellular carcinoma (HCC). To facilitate killing of malignant and/or infected hepatocytes, it is vital to know...
8.
Levink I, Brosens L, Rensen S, Aberle M, Olde Damink S, Cahen D, et al.
Front Med (Lausanne)
. 2022 Feb;
8:751110.
PMID: 35223878
Introduction: Factors underlying antitumor immunity in pancreatic cancer (PC) are poorly understood. We hypothesized that not neoantigen quantity, but quality, is related to immune cell infiltration and survival. Methodology: We...
9.
Bouzid R, Kessler A, Levink I, van den Bosch T, Buschow S, Fuhler G, et al.
Clin Cancer Res
. 2022 Jan;
28(2):425-426.
PMID: 35045959
No abstract available.
10.
Li Y, Yu P, Kessler A, Shu J, Liu X, Liang Z, et al.
Hepatology
. 2021 Aug;
75(1):196-212.
PMID: 34392558
Background And Aims: HEV infection is the most common cause of liver inflammation, but the pathogenic mechanisms remain largely unclear. We aim to explore whether HEV infection activates inflammasomes, crosstalk...